Mediterranean Fever News and Research

RSS

Factors associated with diagnostic delay in Familial Mediterranean Fever

EULAR – The European Alliance of Associations for Rheumatology – held its 2023 annual congress in Milan, Italy. One of the abstracts chosen for presentation in the scientific session on Rheumatic and Musculoskeletal diseases (RMDs) in children and young people, focused on the factors associated with diagnostic delay in FMF, using data from the Juvenile Inflammatory Rheumatism (JIR) cohort.

31 May 2023

Colchicine therapy benefits pediatric long COVID patients suffering from recurring fever

Researchers at National Jewish Health found that a subset of children suffering recurring fevers as a result of long COVID-19, benefited from a daily medication treatment commonly used for gout and periodic fever syndrome.

25 Apr 2023

Scientists characterize type I IFN response during SARS-CoV-2 infection

In a recent study posted to the bioRxiv* preprint server, Canadian researchers assessed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on interferon (IFN) response.

15 Jun 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

COLCORONA study shows that colchicine can reduce complications in certain COVID-19 patients

The Montreal Heart Institute announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine.

28 May 2021

Crafoord Laureate uncovered a new group of rare autoinflammatory diseases

Dan Kastner, USA, has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Race-related differences in genetic determinants of COVID-19 severity

Researchers at the University of Iowa have identified differences in gene expression levels between African Americans and European Americans that may explain the disproportionately higher rates of coronavirus disease 2019 (COVID-19) cases and related deaths among African Americans.

11 Jun 2020

Study reveals molecular pathogenesis of muscular dystrophy-associated cardiomyopathy

In a study recently published in Nature Communications scientists at Okayama University describe the detailed molecular pathogenesis of muscular dystrophy-associated cardiomyopathy in mice lacking the fukutin gene (Fktn), the causative gene for Fukuyama muscular dystrophy.

13 Feb 2020

Novel cellular pathway may clarify how arterial inflammation develops into atherosclerosis

Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis-;deposits of cholesterol, fats and other substances that create plaque, clog arteries and promote heart attacks and stroke. The findings could lead to improved therapies for atherosclerosis, a leading cause of death worldwide.

22 Jun 2018

New findings pinpoint key feature of rare childhood disease that could help fast-track diagnosis

Australian scientists have shown, for the first time, that a family of untethered proteins builds up in the cells of children with a rare and serious genetic condition, known as mevalonate kinase deficiency (MKD).

10 May 2017

VIB researchers develop new tool to diagnose Familial Mediterranean Fever

Researchers at VIB and Ghent University have developed a tool to diagnose Familial Mediterranean Fever (FMF).

24 Nov 2016

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016

Research findings may help better understand genetic origins of Familial Mediterranean Fever

A team of scientists led by Stony Brook University researchers have discovered a new mechanism for a bacterial toxin to inhibit inflammation.

19 Sep 2016

ESC publishes new guidelines on pericardial diseases

New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.

29 Aug 2015

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price.

10 Apr 2015

Sophia Genetics obtains CE-IVD mark for routine genetic tests

Sophia Genetics, the European leader in NGS data analysis, has received the CE-IVD mark for genetic testing of Familial Mediterranean Fever and Hypercholeteromia.

24 Sep 2014

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

The University of Texas Health Science at Houston (UTHealth) announced the opening of a center devoted to researching and treating diseases associated with malfunctioning immune systems.

2 Sep 2011

AutoGenomics introduces first automated molecular assay for Familial Mediterranean Fever

AutoGenomics, a leader in providing automated, molecular testing solutions, announced today that it has launched a new test for the identification of genetic mutations implicated in the development of Familial Mediterranean Fever (FMF). The INFINITI® Familial Mediterranean Fever Panel provides simultaneous multiplexed determination of 13 genetic variants common to more than 10 afflicted ethnicities of Mediterranean origin on the automated INFINITI® Analyzer. FMF is prominently present in the Armenian people, Sephardi Jews, Greeks, Arabs and Turks.

21 Dec 2010

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

16 Dec 2010